Patents by Inventor Nam-Doo Kim

Nam-Doo Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240317730
    Abstract: The present disclosure relates to a heteroaryl derivative and uses thereof. The heteroaryl derivative of the present disclosure exhibits excellent inhibitory activity against EGFR and/or HER2, and thus may be usefully employed as a therapeutic agent for EGFR- and/or HER2-related diseases.
    Type: Application
    Filed: June 1, 2024
    Publication date: September 26, 2024
    Applicant: Voronoi Inc.
    Inventors: Youn Ho Lee, Seon Ah Hwang, In Seob Shim, Hyeon Ho Jeon, Woo Mi Do, Hee Sun Ryu, Jung Beom Son, Nam Doo Kim, Sung Hwan Kim, Hong Ryul Jung, Young Yi Lee
  • Patent number: 12037330
    Abstract: The present disclosure relates to a heteroaryl derivative and uses thereof. The heteroaryl derivative of the present disclosure exhibits excellent inhibitory activity against EGFR and/or HER2, and thus may be usefully employed as a therapeutic agent for EGFR- and/or HER2-related diseases.
    Type: Grant
    Filed: May 16, 2022
    Date of Patent: July 16, 2024
    Assignee: Voronoi Inc.
    Inventors: Youn Ho Lee, Seon Ah Hwang, In Seob Shim, Hyeon Ho Jeon, Woo Mi Do, Hee Sun Ryu, Jung Beom Son, Nam Doo Kim, Sung Hwan Kim, Hong Ryul Jung, Young Yi Lee
  • Publication number: 20240166640
    Abstract: The present disclosure relates to a heteroaryl derivative and uses thereof. The heteroaryl derivative of the present disclosure exhibits excellent inhibitory activity against EGFR and/or HER2, and thus may be usefully employed as a therapeutic agent for EGFR- and/or HER2-related diseases.
    Type: Application
    Filed: January 16, 2024
    Publication date: May 23, 2024
    Applicant: Voronoi Inc.
    Inventors: Youn Ho LEE, Seon Ah Hwang, In Seob Shim, Hyeon Ho Jeon, Woo Mi Do, Hee Sun Ryu, Jung Beom Son, Nam Doo Kim, Sung Hwan Kim, Hong Ryul Jung, Young Yi Lee
  • Publication number: 20240150337
    Abstract: The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin-4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell lines, and thus can be usefully used in the treatment of lung cancer.
    Type: Application
    Filed: September 25, 2023
    Publication date: May 9, 2024
    Inventors: Youn Ho LEE, Ju Hee Kang, Se In Kang, Yi Kyung Ko, Eun Hwa Ko, Hwan Geun Choi, Jung Beom Son, Nam Doo Kim
  • Publication number: 20240025845
    Abstract: Provided is a metastasis-inhibiting composition containing a methylsulfonamide-based derivative compound as an active ingredient. More specifically, the compounds inhibit the activity of chromosome segregation 1-like (CSE1L), and suppress intracellular nuclear transport to inhibit the movement and/or invasion of cancer cells, and thus effectively inhibit metastasis.
    Type: Application
    Filed: September 7, 2021
    Publication date: January 25, 2024
    Inventors: Jong Seog AHN, Sung Kyun KO, Jae Hyuk JANG, Jun Pil JANG, Jae Kyung JUNG, Nam Doo KIM, Bo Yeon KIM, Joon Suk PARK
  • Publication number: 20240025888
    Abstract: The present disclosure relates to a heteroaryl derivative and uses thereof. The heteroaryl derivative of the present disclosure exhibits excellent inhibitory activity against EGFR and/or HER2, and thus may be usefully employed as a therapeutic agent for EGFR- and/or HER2-related diseases.
    Type: Application
    Filed: May 16, 2022
    Publication date: January 25, 2024
    Applicant: Voronoi Inc.
    Inventors: Youn Ho LEE, Seon Ah HWANG, In Seob SHIM, Hyeon Ho JEON, Woo Mi DO, Hee Sun RYU, Jung Beom SON, Nam Doo KIM, Sung Hwan KIM, Hong Ryul JUNG, Young Yi LEE
  • Publication number: 20230322753
    Abstract: The present invention relates to a pharmaceutical composition comprising a compound of the present invention, an isomer thereof, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof as an active ingredient for prevention or treatment of cancer. The compound exhibits high inhibitory activity against epidermal growth factor receptor (EGFR) mutants or at least one of the wild-type or mutant ErbB2 and ErbB4 and as such, can be advantageously used for treatment of the cancer expressing same.
    Type: Application
    Filed: September 18, 2021
    Publication date: October 12, 2023
    Inventors: Younho LEE, Juhee KANG, Yikyung KO, Jung Beom SON, Eunhwa KO, Sung Hwan KIM, Nam Doo KIM, Hwan Geun CHOI
  • Publication number: 20230248740
    Abstract: Disclosed is a pharmaceutical composition for the prevention or treatment of brain cancer, containing a compound capable of penetrating the blood-brain barrier as an active ingredient, the pharmaceutical composition for the prevention or treatment of brain cancer is capable of efficiently penetrating the blood-brain barrier of the brain to thereby effectively inhibit LRRK2 protein expression, and is thus useful in the prevention or treatment of brain cancer.
    Type: Application
    Filed: September 27, 2022
    Publication date: August 10, 2023
    Inventors: Hwan Geun Choi, Jong Bae Park, Eunhwa Ko, Jung Beom Son, Nam Doo Kim, Seung Hoon Lee, Do-Hyun Nam
  • Publication number: 20230183243
    Abstract: The present invention relates to a heteroaryl derivative and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient, and a compound according to an aspect of the present invention, a stereoisomer thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof suppresses kinases, particularly, a TTK kinase, and thus can remarkably suppress the proliferation of cancer cells, and accordingly, can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer.
    Type: Application
    Filed: March 13, 2020
    Publication date: June 15, 2023
    Inventors: U Bin KIM, Youn Ho LEE, Se In KANG, Ju Hee KANG, Seon An HWANG, Da Mi KIM, Seung Su KIM, Myung Ho JUNG, Hyun Kyung KIM, Hong Ryul JUNG, Yeon Sil KIM, Hye Jin JANG, Ji Eun CHOI, Sun Hwa LEE, Jung Beom SON, Nam Doo KIM
  • Publication number: 20230181596
    Abstract: Disclosed is a pharmaceutical composition for the prevention or treatment of brain cancer, containing a compound capable of penetrating the blood-brain barrier as an active ingredient, the pharmaceutical composition for the prevention or treatment of brain cancer is capable of efficiently penetrating the blood-brain barrier of the brain to thereby effectively inhibit LRRK2 protein expression, and is thus useful in the prevention or treatment of brain cancer.
    Type: Application
    Filed: September 27, 2022
    Publication date: June 15, 2023
    Inventors: Hwan Geun Choi, Jong Bae Park, Eunhwa Ko, Jung Beom Son, Nam Doo Kim, Seung Hoon Lee, Do-Hyun Nam
  • Publication number: 20220324874
    Abstract: The present invention relates to an N-containing heteroaryl derivative and a pharmaceutical composition comprising same as an active ingredient for the prevention or treatment of cancer. The derivative exhibits high inhibitory activity against various protein kinases, particularly excellent ret proto-oncogene (RET) enzyme inhibitory ability, and has an excellent effect of inhibiting the proliferation of medullary thyroid cancer cells and lung cancer cells, which express RET fusion genes, and thus the derivative can be effectively used in the treatment of cancer, for example, medullary thyroid cancer or lung cancer, and particularly, can be effectively used in the treatment of cancer in which RET fusion genes are expressed.
    Type: Application
    Filed: May 21, 2020
    Publication date: October 13, 2022
    Inventors: Seo Hyun JO, Hua LI, Hee Sun RYU, Hwan KIM, Ji Yoon SEOK, Sun Hwa LEE, Jung Beom SON, Nam Doo KIM
  • Patent number: 11466000
    Abstract: The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin-4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell lines, and thus can be usefully used in the treatment of lung cancer.
    Type: Grant
    Filed: November 8, 2021
    Date of Patent: October 11, 2022
    Assignee: VORONOI INC.
    Inventors: Youn Ho Lee, Ju Hee Kang, Se In Kang, Yi Kyung Ko, Eun Hwa Ko, Hwan Geun Choi, Jung Beom Son, Nam Doo Kim
  • Publication number: 20220289733
    Abstract: The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin-4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell lines, and thus can be usefully used in the treatment of lung cancer.
    Type: Application
    Filed: March 22, 2022
    Publication date: September 15, 2022
    Inventors: Youn Ho LEE, Ju Hee KANG, Se In KANG, Yi Kyung KO, Eun Hwa KO, Hwan Geun CHOI, Jung Beom SON, Nam Doo KIM
  • Publication number: 20220242870
    Abstract: The present invention relates to a heterocycle-fused pyrimidine derivative compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition for preventing or treating diseases related to one or more protein kinases of FLT3, CDK4, CDK6 and HPK1, comprising the same as an active ingredient, and a method for preventing or treating diseases related to one or more protein kinases of FLT3, CDK4, CDK6 and using the same.
    Type: Application
    Filed: May 18, 2020
    Publication date: August 4, 2022
    Inventors: Seo Hyun JO, Hua LI, Woo Mi DO, Hee Sun RYU, Hwan KIM, Ji Yoon SEOK, Sun Hwa LEE, Jung Beom SON, Nam Doo KIM
  • Publication number: 20220162203
    Abstract: The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin-4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell lines, and thus can be usefully used in the treatment of lung cancer.
    Type: Application
    Filed: March 19, 2020
    Publication date: May 26, 2022
    Inventors: Youn Ho LEE, Ju Hee KANG, Se In KANG, Yi Kyung KO, Eun Hwa KO, Hwan Geun CHOI, Jung Beom SON, Nam Doo KIM
  • Publication number: 20220106307
    Abstract: The present invention relates to a pyrrolo-pyridine derivative compound, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for the prevention or treatment of protein kinase-related diseases. A compound represented by chemical formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, according to the present invention, has excellent inhibitory activity against various protein kinases including DYRK1A, and therefore, the pharmaceutical composition containing the same as an active ingredient can be favorably used in the treatment or prevention of protein kinase-related diseases. Particularly, the pharmaceutical composition can be effectively used in the prevention, treatment, or alleviation of Alzheimer's disease, dementia, or Alzheimer's dementia.
    Type: Application
    Filed: August 10, 2021
    Publication date: April 7, 2022
    Inventors: Hwan Geun CHOI, Eunhwa KO, Joong-heui CHO, Jung Beom SON, Yi Kyung KO, Jin-Hee PARK, So Young KIM, Seock Yong KANG, Seungyeon LEE, Hee Yoon RYU, Nam Doo KIM, Sang Bum KIM, Sun-Hwa LEE, Dayea KIM, Sun Joo LEE, Sungchan CHO, Kyu-Sun LEE, Kweon YU, Miri CHOI, Ja Wook KOO, Hyang-Sook HOE
  • Publication number: 20220073505
    Abstract: The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell limes, and thus can be usefully used in the treatment of lung cancer.
    Type: Application
    Filed: November 8, 2021
    Publication date: March 10, 2022
    Applicants: VORONOI INC., B2SBIO INC., VORONOIBIO INC., B2SBIO INC.
    Inventors: Youn Ho LEE, Ju Hee KANG, Se In KANG, Yi Kyung KO, Eun Hwa KO, Hwan Geun CHOI, Jung Beom SON, Nam Doo KIM
  • Patent number: 11208412
    Abstract: The present invention relates to a novel pyrrolo-pyrimidine derivative compound, a preparation method therefor, and a pharmaceutical composition comprising the same compound as an effective ingredient for preventing or treating a protein kinase-related disease. The compound represented by Chemical Formula 1 according to the present invention, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an effective ingredient has outstanding inhibitory activity against LRRK2 kinase and against phosphorylation in the NIH-3T3 cell line, which is an LRRK2-expressing cell line, and NCC01 and 448T cell lines, which are both derived from patients with brain tumors. Verified to have inhibitory activity against various protein kinases in addition to LRRK2, the compound can find effective applications in the treatment or prevention of protein kinase-related diseases.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: December 28, 2021
    Assignees: Daegu-Gyeongbuk Medical Innovation Foundation, National Cancer Center, Samsung Life Public Welfare Foundation
    Inventors: Hwan Geun Choi, Jong Bae Park, Eunhwa Ko, Jung Beom Son, Joong-heui Cho, Yi Kyung Ko, Jin-Hee Park, So Young Kim, Seock Yong Kang, Seungyeon Lee, Nam Doo Kim, Yunho Lee, Sun-Hwa Lee, Dayea Kim, Sun Joo Lee, Jae Hyun Bae, Eunmi Hong, Tae-ho Jang, Sang Bum Kim, Seung Hoon Lee, Do-Hyun Nam
  • Patent number: 11117892
    Abstract: The present invention relates to a pyrrolo-pyridine derivative compound, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for the prevention or treatment of protein kinase-related diseases. A compound represented by chemical formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, according to the present invention, has excellent inhibitory activity against various protein kinases including DYRK1A, and therefore, the pharmaceutical composition containing the same as an active ingredient can be favorably used in the treatment or prevention of protein kinase-related diseases. Particularly, the pharmaceutical composition can be effectively used in the prevention, treatment, or alleviation of Alzheimer's disease, dementia, or Alzheimer's dementia.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: September 14, 2021
    Inventors: Hwan Geun Choi, Eunhwa Ko, Joong-heui Cho, Jung Beom Son, Yi Kyung Ko, Jin-Hee Park, So Young Kim, Seock Yong Kang, Seungyeon Lee, Hee Yoon Ryu, Nam Doo Kim, Sang Bum Kim, Sun-Hwa Lee, Dayea Kim, Sun Joo Lee, Sungchan Cho, Kyu-Sun Lee, Kweon Yu, Miri Choi, Ja Wook Koo, Hyang-Sook Hoe
  • Publication number: 20210267997
    Abstract: Disclosed is a pharmaceutical composition for the prevention or treatment of brain cancer, containing a compound capable of penetrating the blood-brain barrier as an active ingredient, the pharmaceutical composition for the prevention or treatment of brain cancer is capable of efficiently penetrating the blood-brain barrier of the brain to thereby effectively inhibit LRRK2 protein expression, and is thus useful in the prevention or treatment of brain cancer.
    Type: Application
    Filed: February 23, 2018
    Publication date: September 2, 2021
    Inventors: Hwan Geun Choi, Jong Bae Park, Eunhwa Ko, Jung Beom Son, Nam Doo Kim, Seung Hoon Lee, Do-Hyun Nam